NICE Seeks More Data From Abbott On Humira In Psoriatic Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. agency’s preliminary appraisal on cost effectiveness does not call for recommending adalimumab.
You may also be interested in...
U-Turn: NICE Recommends Rituximab, Humira In Arthritis Indications After Second Review
U.K. agency reverses unfavorable preliminary opinions based on submissions from Roche and Abbott.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.